Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Sage Potash Corp. (TSXV: SAGE) (OTC: SGPTF) ("Sage" or the "Company") is pleased to announce that it has closed its ...

"Sage has made a strong start to the year, achieving broad-based revenue growth in line with expectations, despite the ongoing macroeconomic uncertainty," Chief Financial Officer Jonathan Howell said ...

We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

its finance chief, has held that role for nearly seven years. Their length of service means that identifying successors for both will be a priority for Mr Duff in the coming years, with Sage's ...

Publish What You Pay (PWYP), a global advocacy network campaigning for a fairer energy transition, has doubled its capacity to manage restricted funds ...